Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000350484 | SCV000342951 | likely pathogenic | not provided | 2016-06-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855213 | SCV002161290 | pathogenic | Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementation group Q | 2020-11-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with ERCC4-related conditions. ClinVar contains an entry for this variant (Variation ID: 288748). This variant is present in population databases (rs772432152, ExAC 0.009%). This sequence change creates a premature translational stop signal (p.Asn308Ilefs*6) in the ERCC4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ERCC4 are known to be pathogenic (PMID: 9580660). |
Fulgent Genetics, |
RCV005016680 | SCV005645242 | likely pathogenic | Xeroderma pigmentosum, group F; XFE progeroid syndrome; Fanconi anemia complementation group Q | 2024-01-22 | criteria provided, single submitter | clinical testing |